SEARCH

SEARCH BY CITATION

References

  • 1
    Natanson C , Kern SJ , Lurie P , Banks SM , Wolfe SM . Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299:230412.
  • 2
    Berger K , Frey L , Spannagl M , Schramm W . [Health economic aspects of the use of blood and blood products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006;49:6472.
  • 3
    Shander A , Hofmann A , Gombotz H , Theusinger OM , Spahn DR . Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007;21:27189.
  • 4
    Kanavos P , Yfantopoulos J , Vandoros C , Politis C . The economics of blood: gift of life or a commodity? Int J Technol Assess Health Care 2006;22:33843.
  • 5
    Greinacher A , Fendrich K , Alpen U , Hoffmann W . Impact of demographic changes on the blood supply: Mecklenburg-West Pomerania as a model region for Europe. Transfusion 2007;47:395401.
  • 6
    Zou S , Musavi F , Notari EP 4th , Fang CT . Changing age distribution of the blood donor population in the United States. Transfusion 2008;48:2517.
  • 7
    Podszun R . Kartellrecht in wettbewerbsfernen Branchen – das Beispiel Blutspendewesen. ZWeR 2008;2:193207.
  • 8
    Blood supply and demand. Lancet 2005;365:2151.
  • 9
    Pirmohamed M , James S , Meakin S , Green C , Scott AK , Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:159.
  • 10
    Carrasco-Garrido P , de Andres LA , Barrera VH , de Miguel GA , Jimenez-Garcia R . Trends of adverse drug reactions related-hospitalizations in Spain (2001–2006). BMC Health Serv Res 2010;10:287.
  • 11
    Wu TY , Jen MH , Bottle A , Molokhia M , Aylin P , Bell D et al. Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009. J R Soc Med 2010;103:23950.
  • 12
    Rottenkolber D , Schmiedl S , Rottenkolber M , Farker K , Salje K , Mueller S et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf 2011;20:62634.
  • 13
    Thurmann PA , Schmitt K . [Detection and evaluation of adverse drug reactions]. Med Klin (Munich) 1998;93:68792.
  • 14
    Schneeweiss S , Hasford J , Gottler M , Hoffmann A , Riethling AK , Avorn J . Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:28591.
  • 15
    Davies EC , Green CF , Taylor S , Williamson PR , Mottram DR , Pirmohamed M . Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009;4:e4439.
  • 16
    Pardo Cabello AJ , Gonzalez Contreras LG , Manzano Gamero MV , Gomez Jimenez FJ , Puche Canas E . Prevalence of fatal adverse drug reactions in hospitalized patients. Int J Clin Pharmacol Ther 2009;47:596602.
  • 17
    Schmiedl S , Mertens A , Richter S , Szymanski J , Krahwinkel W , Schroth U et al. Detection of clinically relevant adverse drug reactions (ADRs) in departments of internal medicine. Eur J Clin Pharmacol 2005;61:71920.
  • 18
    Apretna E , Haramburu F , Taboulet F , Begaud B . [Medical and socio-economical impact of drug-induced adverse reactions]. Presse Med 2005;34:2716.
  • 19
    Classen DC , Pestotnik SL , Evans RS , Lloyd JF , Burke JP . Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:3016.
  • 20
    Goettler M , Schneeweiss S , Hasford J . Adverse drug reaction monitoring–cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997;6(Suppl 3):S7990.
  • 21
    Muehlberger N , Schneeweiss S , Hasford J . Adverse drug reaction monitoring–cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf 1997;6(Suppl 3):S717.
  • 22
    Schneeweiss SG , Goettler M , Hasford J . Adverse drug events in hospitalized patients. JAMA 1997;277:13523; author reply 3–4.
  • 23
    Beijer HJ , de Blaey CJ . Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24:4654.
  • 24
    Ducharme MM , Boothby LA . Analysis of adverse drug reactions for preventability. Int J Clin Pract 2007;61:15761.
  • 25
    Rodriguez-Monguio R , Otero MJ , Rovira J . Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21:62350.
  • 26
    Hippius M , Humaid B , Sicker T , Hoffmann A , Gottler M , Hasford J . Adverse drug reaction monitoring–digitoxin overdosage in the elderly. Int J Clin Pharmacol Ther 2001;39:33643.
  • 27
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B(R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2B/Step4/E2B_R2__Guideline.pdf. 2001. (last accessed 24 September 2010).
  • 28
    Begaud B , Evreux JC , Jouglard J , Lagier G . [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie 1985;40:1118.
  • 29
    Hartwig SC , Siegel J , Schneider PJ . Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:222932.
  • 30
    Schumock GT , Thornton JP . Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.
  • 31
    Pape HC , Grotz M , Schwermann T , Ruchholtz S , Lefering R , Rieger M et al. [The development of a model to calculate the cost of care for the severely injured–an initiative of the Trauma Register of the DGU]. Unfallchirurg 2003;106:34857.
  • 32
    Spalding GJ , Hartrumpf M , Sierig T , Oesberg N , Kirschke CG , Albes JM . [Bedside thromboelastography. Cost reduction in cardiac surgery]. Anaesthesist 2007;56:76571.
  • 33
    Paeßens B . Transfusion von Blutkomponenten zum Management von chemotherapieinduzierten hämatologischen Nebenwirkungen. Analyse von Behandlungsmustern, Ressourcenverbrauch und Kosten aus der Perspektive eines deutschen Universitätsklinikums. Dissertation LMU München, Munich, 2008.
  • 34
    WHO. Anatomical Therapeutic Chemical (ATC) Classification Index. WHO Collaborating Centre for Drug Statistics Methodology, Geneva, 1992.
  • 35
    Doubilet P , Begg CB , Weinstein MC , Braun P , McNeil BJ . Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:15777.
  • 36
    Brown EG , Wood L , Wood S . The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:10917.
  • 37
    Mozzicato P . MedDRA. An Overview of the Medical Dictionary for Regulatory Activities. Pharm Med 2009;23:6575.
  • 38
    Paul Ehrlich Institute. Blood products. http://www.pei.de/cln_101/nn_162408/EN/medicinal-products/blutprodukte-en/blutprodukte-node-en.html?__nnn=true 2010. (last accessed on 12 November 2010).
  • 39
    Meßmann H , Gruber R . Obere und untere gastrointestinale Blutung. In: Schölmerich J , Holstege A , Hohenberger W , Zirngibl H (eds). Gastroenterologische Therapie. Urban und Schwarzenberg, Munich, 1994; 26872.
  • 40
    Wagner FF , Kubanek B . Therapie mit Erythrozyten. In: Mueller-Eckhardt C , Kiefel V (eds). Transfusionsmedizin Grundlagen – Therapie – Methodik. Springer, Berlin, Heidelberg, 2004;37085.
  • 41
    Kretschmer V , Gombotz H , Rump G . Transfusionsmedizin – Klinische Hämotherapie. Thieme, Stuttgart, 2008.
  • 42
    Federal Statistical Office. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle). Federal Statistical Office Germany, (ed.). Federal Statistical Office Germany, Wiesbaden, 2006.
  • 43
    Federal Statistical Office. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle). Federal Statistical Office Germany, (ed.). Federal Statistical Office Germany, Wiesbaden, 2007.
  • 44
    Huic M , Mucolic V , Vrhovac B , Francetic I , Bakran I , Giljanovic S . Adverse drug reactions resulting in hospital admission. Int J Clin Pharmacol Ther 1994;32:67582.
  • 45
    Parker DR , Luo X , Jalbert JJ , Assaf AR . Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ 2011;14:27987.
  • 46
    Hallas J , Lauritsen J , Villadsen HD , Gram LF . Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:43844.
  • 47
    Gutthann SP , Garcia Rodriguez LA , Raiford DS . Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:1824.
  • 48
    Lagnaoui R , Moore N , Fach J , Longy-Boursier M , Begaud B . Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000;56:1816.
  • 49
    Dormann H , Criegee-Rieck M , Neubert A , Egger T , Geise A , Krebs S et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003;26:35362.
  • 50
    Kongkaew C , Noyce PR , Ashcroft DM . Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008;42:101725.
  • 51
    van der Hooft CS , Sturkenboom MC , van Grootheest K , Kingma HJ , Stricker BH . Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006;29:1618.
  • 52
    Ackerman SJ , Klumpp TR , Guzman GI , Herman JH , Gaughan JP , Bleecker GC et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 2000;40:145762.
  • 53
    Cantor SB , Hudson DV Jr , Lichtiger B , Rubenstein EB . Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998;16:236470.
  • 54
    Agrawal S , Davidson N , Walker M , Gibson S , Lim C , Morgan CL et al. Assessing the total costs of blood delivery to hospital oncology and haematology patients. Curr Med Res Opin 2006;22:19039.
  • 55
    Kuhne F , Mittendorf T , Germing U , Tesch H , Weinberg R , Grabenhorst U et al. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective. Ann Hematol 2010;89:123947.
  • 56
    Davies L , Brown TJ , Haynes S , Payne K , Elliott RA , McCollum C . Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006;10:iii–iv, ix–x, 1210.
  • 57
    Glenngard AH , Persson U , Soderman C . Costs associated with blood transfusions in Sweden–the societal cost of autologous, allogeneic and perioperative RBC transfusion. Transfus Med 2005;15:295306.
  • 58
    Funk MB , Gunay S , Lohmann A , Henseler O , Keller-Stanislawski B . [Evaluation of measures aimed to reduce serious adverse transfusion reactions (hemovigilance data from 1997 to 2008)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010;53:34756.
  • 59
    Amin M , Fergusson D , Wilson K , Tinmouth A , Aziz A , Coyle D et al. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion 2004;44:147986.
  • 60
    Shander A , Hofmann A , Ozawa S , Theusinger OM , Gombotz H , Spahn DR . Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:75365.
  • 61
    Greinacher A , Fendrich K , Hoffmann W . Demographic changes: the impact for safe blood supply. Transfus Med Hemother 2010;37:1418.
  • 62
    Katalinic A , Peters E , Beske F , Pritzkuleit R . Projection of morbidity 2030 and 2050: impact for the national health system and blood supply. Transfus Med Hemother 2010;37:1559.
  • 63
    Henseler O , Heiden M , Haschberger B , Hesse J , Seitz R . [Report on notifications pursuant to Section 21 of the German Transfusion Act for the years 2008 and 2009]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010;53:1089103.
  • 64
    Kolh P , Wijns W , Danchin N , Di Mario C , Falk V , Folliguet T et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010;38(Suppl):S152.
  • 65
    Lundkvist J , Jonsson B . Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004;18:27580.
  • 66
    Johnson JA , Bootman JL . Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm 1997;54:5548.
  • 67
    Grandt D , Friebel H , Müller-Oerlinghausen B . Arzneitherapie(un)sicherheit. Notwendige Schritte zur Verbesserung der Patientensicherheit bei medikamentöser Therapie. Deutsches Ärzteblatt 2005;102:A50915.